ֱ

Rinvoq Approved for UC; HCC Combo Flops; Disney Grants Pass to IBS Patient

— News and commentary from the world of gastroenterology and hepatology

MedpageToday
A computer rendering of an endoscope.

The FDA approved upadacitinib (Rinvoq) to treat adults with moderately to severely active ulcerative colitis with an inadequate response or intolerance to at least one tumor necrosis factor (TNF) blocker, drugmaker .

Non-invasive among patients with type 2 diabetes. (Clinical Gastroenterology and Hepatology)

Cold snare resection was safe and ranging 6-15 mm in size, a randomized trial found. (Gastrointestinal Endoscopy)

Exelixis said it of cabozantinib (Cabometyx) in combination with atezolizumab (Tecentriq) for untreated advanced hepatocellular carcinoma (HCC) after a phase III trial found no survival improvement over sorafenib (Nexavar).

A controversial TikTok video showed a woman bragging about how she that allowed her to skip lines at Disney theme parks. (Newsweek)

COVID vaccination in Poland against serious complications of SARS-CoV-2 infection, despite being on immunosuppressive agents. (Transplantation Proceedings)

Within 6 months of each other, a young Denver couple were each diagnosed with . (KUSA)

A new externally validated model after endoscopic eradication of Barrett's esophagus for those with dysplasia or early cancer. (Gastroenterology)

  • author['full_name']

    Zaina Hamza is a staff writer for ֱ, covering Gastroenterology and Infectious disease. She is based in Chicago.